Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders

Apathy is one of the most frequent behavioral disturbances in many neurodegenerative disorders and is known to have a negative impact on the disease progression, particularly in Alzheimer's disease. Therapeutic options are currently limited and non-pharmacological approaches should constitute f...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2020-01, Vol.10, p.1581-1581
Main Authors: Bogdan, Anamaria, Manera, Valeria, Koenig, Alexandra, David, Renaud
Format: Article
Language:English
Subjects:
Alzheimer’s disease
amotivation
apathy
Cognitive science
neurodegenerative disorders
Pharmacology
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Apathy is one of the most frequent behavioral disturbances in many neurodegenerative disorders and is known to have a negative impact on the disease progression, particularly in Alzheimer's disease. Therapeutic options are currently limited and non-pharmacological approaches should constitute first line treatments. Pharmacological agents likely to reduce apathy levels are lacking. The objective of the present article is to review recent pharmacological treatments for apathy in neurodegenerative disorders. The Pubmed database was searched with a particular focus on articles published as of January 2017. Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results. Treatment duration and samples sizes may have however decreased the validity of previous results. Ongoing studies involving more participants/treatment duration or distinct neural pathways may provide new insights in the treatment of apathy in neurodegenerative disorders.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.01581